Sugi Predict

Sugi Predict / Compounds / SCHEMBL6756017

SCHEMBL6756017

SCHEMBL6756017

CCOC(=O)c1ccc(C=Cc2cc3c(cc2C)C(C)(C)CC=C3O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RARA P10276 7/20 0.48
▸ RARB P10826 6/20 0.48
▸ RARG P13631 4/20 0.48
▸ RXRA P19793 1/20 0.40
▸ NR2E1 Q9Y466 1/20 0.40
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CA14 Q9ULX7 2/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ MAPK1 P28482 2/20 0.36
▸ PPARG P37231 1/20 0.35
▸ PDK2 Q15119 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6752848 0.87 RARA (0.46) RARARARBRARGRXRANR2E1
SCHEMBL8025898 0.87 RARA (0.46) RARARARBRARGRXRANR2E1
SCHEMBL8016189 0.82 RARA (0.43) RARARARBRARGRXRANR2E1
SCHEMBL8018376 0.82 RARA (0.54) RARARARBRARGRXRACA12
SCHEMBL10846840 0.82 RARA (0.72) RARARARBRARGRXRACA12
SCHEMBL10846838 0.82 RARA (0.72) RARARARBRARGRXRACA12
SCHEMBL6756015 0.80 RXRA (0.46) RARARARBRARGRXRACA12
SCHEMBL14159923 0.76 RARA (0.55) RARARARBRARGRXRACA12
SCHEMBL7678420 0.75 RARA (0.61) RARARARBRARGRXRANR2E1
SCHEMBL6398148 0.73 RARB (0.62) RARARARBRARGRXRANR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713515-B2 ADMINISTERING BENZYL, NAPHTHYL ACID DERIVATIVES BRISTOL MYERS SQUIBB COMPANY 2004-03-30 — — US disclosed
US-6624154-B1 Invention relates to compositions comprising a retinoid X receptor agonist and an agent capable of activating protein kinase A. The invention also relates to methods of treating hyperproliferative diseases by administering a retinoid X BRISTOL-MYERS SQUIBB COMPANY 2003-09-23 — — US disclosed
US-20020120006-A1 Retinoic acid receptor antagonists as promoters of angiogenesis BRISTOL-MYERS SQUIBB COMPANY 2002-08-29 — — US disclosed
WO-2002022113-A2 RETINOIC ACID RECEPTOR ANTAGONISTS AS PROMOTERS OF ANGIOGENESIS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-03-21 — — WO disclosed
EP-1173061-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES Bristol-Myers Squibb Company (US) 2002-01-23 — — EP disclosed
WO-2000064260-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2000-11-02 — — WO disclosed
WO-2000059861-A1 SELECTIVE RETINOIC ACID ANALOGS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120006-A1 Retinoic acid receptor antagonists as promoters of angiogenesis RARB, RARG, RARA RARA 3/4885RARB 1/4885RARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.